Studies have implicated recurrent somatic mutations in PRKAR1A, as well as alterations in cAMP pathway genes such as PRKACA and PDE11A, suggesting a shared pathogenic mechanism between sporadic and familial myxomas [6]. Here, PRKAR1A is linked to myxoma.